Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum CCM 7952
- Development stage
- Preclinical
- Lead developer
- Institute of Microbiology ASCR
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum CCM 7952 is a specific probiotic bacterial strain of the subspecies *longum* that has been identified for its potent immunomodulatory and gut-protective properties. Originally isolated from the fecal samples of healthy infants or adults, this strain is characterized by its ability to preserve the integrity of the intestinal epithelial barrier. It achieves this by maintaining the expression and proper localization of tight junction proteins, specifically zonulin-1 and occludin, which are often disrupted in inflammatory conditions. Preclinical studies demonstrate that CCM 7952 can prevent the development of acute ulcerative colitis and allergic sensitization. Its mechanism involves signaling through Toll-like receptor 2 (TLR2) and Nucleotide-binding oligomerization domain-containing protein 2 (NOD2), leading to a reduction in pro-inflammatory cytokines such as TNF-α and IFN-γ in the mesenteric lymph nodes.
- Other names
- Bifidobacterium longum ssp. longum CCM 7952
02
Targets
TJP1 (Tight junction protein 1 (ZO-1))NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)OCLN (Occludin)TLR2 (Toll-like Receptor 2)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Bifidobacterium longum CCM 7952.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium longum CCM 7952.